Key result
Sodium-glucose cotransporter 2 inhibitors potentially prevent atrial fibrillation by balancing sodium and calcium handling disorders and mitigating mitochondrial dysfunction in atrial myocytes.
Why the study?
SGLT2 inhibitors have been implicated in decreasing AF events, but the underlying electrophysiological and cellular mechanisms require clarification.
Do SGLT2 inhibitors prevent atrial fibrillation in patients with type 2 diabetes and heart failure?
Design
Review
Authors
Loading...
May support SGLT2i for AF risk reduction in T2D via ion/mitochondrial effects; leaves open need for dedicated RCTs.
Do SGLT2 inhibitors prevent atrial fibrillation in patients with type 2 diabetes and heart failure?
This review highlights the potential mechanisms by which SGLT2 inhibitors prevent atrial fibrillation, specifically through improving ion handling and mitochondrial function in atrial myocytes.
Peng et al. (2020) conducted a review in Atrial Fibrillation. Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) was evaluated. Sodium-glucose cotransporter 2 inhibitors potentially prevent atrial fibrillation by balancing sodium and calcium handling disorders and mitigating mitochondrial dysfunction in atrial myocytes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: